[{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Simpinicline","moa":"Neuronal acetylcholine receptor; alpha3\/beta4 | Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Oyster Point Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Immunology","graph2":"Phase IV","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Oyster Point Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Oyster Point Pharma \/ Oyster Point Pharma"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0.41999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.41999999999999998,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Viatris"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.41999999999999998,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Viatris"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0.22,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.22,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Oyster Point Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Oyster Point Pharma \/ Oyster Point Pharma"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Oyster Point Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Oyster Point Pharma \/ Oyster Point Pharma"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hemigalactarate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OC-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OC-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oyster Point Pharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Oyster Point Pharma
Details :
Varenicline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Details :
Tyrvaya (Varenicline) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Details :
Varenicline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sjogren's Syndrome.
Details :
TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Details :
With the combination of Viatris' R&D and regulatory capabilities, along with Oyster Point's commercial asset, Tyrvaya (varenicline), for the treatment of dry eye disease, the Company has the foundation to create a leading global ophthalmology franchise.
Details :
Varenicline Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.
Details :
TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Details :
TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Details :
Varenicline Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Details :
TYRVAYA® (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
Reset All
